The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40 in a...
Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine )
Also on site :
- 'Hissing door mid-air': AI flight to Hong Kong spooks flyers; crew use napkins to 'fix' issue
- Prabowo hails BRICS entry, reaffirms Indonesia’s non-aligned stance
- Israel-Iran war stretches into a second week without diplomatic breakthrough